Concepedia

Sandra Milev

SM

Statistics

Publications

4

Citations

128

H-Index

4

Active since

2019

Affiliations

Ithaka Harbors(Current)

Pfizer (United States)

Sandra Milev is an author at Ithaka Harbors specializing in cost-effectiveness modeling, treatment cost analysis, and cost-effectiveness comparison.

Publications per year

2019–2022

4

Publications

4

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

Alexia Kieffer, Matthieu Beuvelet, Aditya Sardesai et al. · The Journal of Infectious Diseases · 2022 · 82 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States

Sandra Milev, Marco DiBonaventura, Peter Quon et al. · Journal of Medical Economics · 2019 · 18 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany

Aditya Sardesai, Peter Quon, Sandra Milev et al. · Journal of Medical Economics · 2021 · 15 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department

Uwe Siebert, Sandra Milev, Denise Zou et al. · The American Journal of Cardiology · 2021 · 13 citations · Full text

Medicine, Cardiology, Internal Medicine +9

1–4 of 4